Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120

Benzinga · 1d ago
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.